Bausch + Lomb Corporation (BLCO)
Bausch + Lomb Corporation operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Vaughan, ON, CA. The stock last traded at $16.49, down 2.25% on the session, giving a market capitalisation of $5.89B. On trailing twelve-month figures it carries a trailing P/E of -34.48, a net margin of -3.2%. Its beta of 0.55 implies it has historically moved less than the broad market.
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Bausch + Lomb Corporation is most often compared with the following Healthcare names: